Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label PARP. Show all posts
Showing posts with label PARP. Show all posts
Tuesday, May 01, 2012

paywalled: Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery: Variability of PARP Activity

›
Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery: Variability of PARP Activity Abstract Purpose: T...
Monday, April 16, 2012

open access: Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations (technical)

›
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations - UKPMC Article - UK PubMed Central Abstract Uti...
Tuesday, April 03, 2012

abstract: Rare Mutations in XRCC2 Increase the Risk of Breast Cancer.

›
 Blogger's Note : see recent post for a null finding XRCC/Lynch Syndrome Rare Mutations in XRCC2 Increase the Risk of Breast Cancer. :...
Friday, March 30, 2012

science daily: New breast cancer susceptibility gene (brca)

›
New breast cancer susceptibility gene ".... XRCC2 may also provide a new target for chemotherapy. "A type of drug called a PAR...
Tuesday, March 27, 2012

Medical News:Data Confirm PARP Inhibitor (Olaparib) Slows Ovarian Ca - in Meeting Coverage, SGO from MedPage Today

›
Medical News:Data Confirm PARP Inhibitor Slows Ovarian Ca - in Meeting Coverage, SGO from MedPage Today Action Points ...
Tuesday, March 20, 2012

abstract: Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery - Variability of Poly (ADP-Ribose) Polymerase Activity.

›
Wiki:  Poly ADP ribose polymerase: Poly (ADP-ribose) polymerase ( PARP ) is a family of proteins involved in a number of cellular proce...
Friday, March 16, 2012

MBCC: PARP Inhibitors for Breast Cancer—Which Subpopulation to Target? - Cancer Network (BRCA, triple-negative breast...)

›
MBCC: PARP Inhibitors for Breast Cancer—Which Subpopulation to Target? - Cancer Network "Speaking at the 29th Annual Miami Breast Can...
Tuesday, February 21, 2012

press release: Mapping of protein inhibitors facilitates development of tailor-made anticancer agents

›
Press release (reducing side effects of parp inhibitors)   Karolinska Institutet
Saturday, February 18, 2012

updated - link to full free paper: Review: Therapeutic strategies in epithelial ovarian cancer (references clear cell ovarian)

›
 Blogger's Note: numerous references to clear cell ovarian cancer as per Japanese historical ovarian cancer research direct link to...
Thursday, January 19, 2012

Hereditary ovarian cancer: Beyond the usual suspects - abstract (Fanconi anemia–BRCA,PARP, RAD51C, RAD51D,BRIP1

›
Blogger's Note: see post Myriad Genetics  rights/RAD51C .....With at least 16 genes implicated in hereditary ovarian cancer to dat...
Tuesday, January 10, 2012

phase 11 - Cancer Research UK launches 'outpatients' (oral)trial of breast and ovarian cancer drug (BRCA/serous cell type - AG-014699 known as Rucaparib or CO-338 - PARP inhibitor)

›
" Cancer Research UK’s Drug Development Office has re-launched a trial of a promising drug to treat inherited breast and ovarian can...
Thursday, August 11, 2011

Clinical Oncology News - Mixed News on PARP Inhibitors Presented at ASCO Meeting

›
Monday, July 18, 2011

Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells-abstract

›
"5-Fluorouracil (5-FU) and 5-fluorodeoxyuridine (FdUrd, floxuridine) have activity in multiple tumors, and both agents undergo intracel...
Friday, June 03, 2011

Search Results: parp - 2011 ASCO Abstracts

›
Search: parp Found 141 documents
Thursday, June 02, 2011

press release: Pfizer Licenses PARP Inhibitor To Clovis Oncology (PF-01367338)

›
"...PF-01367338 would be developed by Clovis as both a monotherapy and in combination with chemotherapeutic agents for the potential ...
Friday, May 20, 2011

May 20th Medscape - PARP Inhibitor Improves Outcomes in Ovarian Cancer - olaparib

›
Tuesday, March 08, 2011

worth reading - Medical News: SGO: PARP Inhibitor Active in Ovarian Cancer - in Meeting Coverage, SGO from MedPage Today

›
......"Antitumor activity was observed in heavily pretreated BRCA1 and BRCA2 mutation carriers, and preliminary antitumor activity was...
Thursday, February 03, 2011

MSKCC (Memorial Sloan Kettering) Winter 2011 newsletter Molecular Medicine for Ovarian and Endometrial Cancer - Douglas A Levine

›
Note: includes reference to PARP inhibitors Download Article - Update in Gynecologic Oncology , Winter 2011
Monday, January 17, 2011

full free access: Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic - A Cancer Journal for Clinicians - Wiley Online Library

›
see also:    Table 1 .  DNA Repair Pathways (Lynch Syndrome, BRCA 1/2, FANC, ATM, MYH ;   Table 2 .  PARP Inhibitor Clinical Trials; ...
Wednesday, November 17, 2010

PARP (1 and 2) inhibitor, MK-4827, shows anti-tumor activity in first trial in humans (mutation/non mutation carriers)

›
"He gave a possible explanation as to why patients with cancers that were not caused by BRCA1/2 mutations also responded to the PARP i...